When it comes to a hair loss cure or groundbreaking new hair loss treatment, Samumed is one of the favorites to come out with something significant in the next several years. I have covered Samumed and its SM04554 hair loss product numerous times on this blog in the past. The product works via the activation of the Wnt signaling pathway and subsequent epithelial β-catenin signaling.
The company’s CEO Dr. Osman Kibar has been widely covered in the media, including a cover appearance on Forbes magazine in 2016. They also got publicity in 2018 in Business Insider after announcing plans to go public in 3-4 years.
Earlier today, reader “chris2” pointed out that Samumed is starting its final Phase 3 clinical trial for its SM04554 product. This news is provided in Samumed’s latest monthly newsletter (subscribe here). The best part of this story is that these trials will entail 625 patients, which is incredible. I do not remember hair loss companies ever testing their product on so many people in clinical trials. More often than not, they test on less than 50 human volunteers.
It is not surprising that Samumed can go all out with these trials. They have been valued at a massive $12 billion, and earlier this month, they received $438 million in new equity funding.
So in just this summer of 2018, we have received highly favorable news from: Samumed, Cassiopea, Histogen, RiverTown, Follicum, Organ Technologies/RIKEN/Tsuji. I hope Follica and Shiseido are next in line.